IGC Latest Press Releases

-- October 13, 2026 --

IGC Pharma Unveils PRISM AI Platform to Move Alzheimer's Risk Prediction to Brain-Health Action and Commercial Deployment ACCESS Newswire 8:00 AM

-- September 28, 2026 --

IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026 ACCESS Newswire 8:00 AM

-- August 17, 2026 --

IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure ACCESS Newswire 8:30 AM

-- August 11, 2026 --

IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout ACCESS Newswire 8:30 AM

-- July 29, 2026 --

IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign ACCESS Newswire 8:30 AM

-- July 9, 2026 --

IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer's Data Harmonization Time by 90% in Representative Workflow ACCESS Newswire 9:00 AM

-- July 7, 2026 --

IGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company ACCESS Newswire 9:00 AM

-- June 23, 2026 --

IGC Pharma's AHA Agentic AI Platform Reduces Alzheimer's Data Harmonization Time by 90% in Representative Workflow ACCESS Newswire 8:30 AM

-- June 11, 2026 --

IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis ACCESS Newswire 8:30 AM

-- June 9, 2026 --

Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts ACCESS Newswire 8:30 AM

-- June 2, 2026 --

IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis ACCESS Newswire 8:30 AM

Market Data Delayed 15 Minutes